495 related articles for article (PubMed ID: 26672686)
1. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.
Robin P; Le Roux PY; Planquette B; Accassat S; Roy PM; Couturaud F; Ghazzar N; Prevot-Bitot N; Couturier O; Delluc A; Sanchez O; Tardy B; Le Gal G; Salaun PY;
Lancet Oncol; 2016 Feb; 17(2):193-199. PubMed ID: 26672686
[TBL] [Abstract][Full Text] [Related]
2. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism.
Robin P; Le Roux PY; Le Moigne E; Planquette B; Prévot-Bitot N; Roy PM; Pastre J; Merah A; Couturaud F; Le Gal G; Salaun PY
Thromb Res; 2017 Jul; 155():6-9. PubMed ID: 28460260
[No Abstract] [Full Text] [Related]
3. Screening for occult malignancy with FDG-PET/CT in patients with unprovoked venous thromboembolism.
Alfonso A; Redondo M; Rubio T; Del Olmo B; Rodríguez-Wilhelmi P; García-Velloso MJ; Richter JA; Páramo JA; Lecumberri R
Int J Cancer; 2013 Nov; 133(9):2157-64. PubMed ID: 23616232
[TBL] [Abstract][Full Text] [Related]
4. A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism.
Rondina MT; Wanner N; Pendleton RC; Kraiss LW; Vinik R; Zimmerman GA; Heilbrun M; Hoffman JM; Morton KA
Thromb Res; 2012 Jan; 129(1):22-7. PubMed ID: 21802118
[TBL] [Abstract][Full Text] [Related]
5. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.
Robin P; Kumar S; Salaun PY; Le Roux PY; Couturaud F; Planquette B; Merah A; Roy PM; Thavorn K; Le Gal G
Thromb Res; 2018 Nov; 171():97-102. PubMed ID: 30268859
[TBL] [Abstract][Full Text] [Related]
6. Screening for Occult Cancer in Unprovoked Venous Thromboembolism.
Carrier M; Lazo-Langner A; Shivakumar S; Tagalakis V; Zarychanski R; Solymoss S; Routhier N; Douketis J; Danovitch K; Lee AY; Le Gal G; Wells PS; Corsi DJ; Ramsay T; Coyle D; Chagnon I; Kassam Z; Tao H; Rodger MA;
N Engl J Med; 2015 Aug; 373(8):697-704. PubMed ID: 26095467
[TBL] [Abstract][Full Text] [Related]
7. Performance of 18F-fluorodesoxyglucose positron-emission tomography combined with low-dose computed tomography for cancer screening in patients with unprovoked venous thromboembolism.
Robin P; Le Roux PY; Lacut K; Planquette B; Prévot-Bitot N; Lavigne C; Pastre J; Merah A; Le Gal G; Salaun PY
PLoS One; 2017; 12(6):e0178849. PubMed ID: 28570648
[TBL] [Abstract][Full Text] [Related]
8. Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial.
Nestle U; Schimek-Jasch T; Kremp S; Schaefer-Schuler A; Mix M; Küsters A; Tosch M; Hehr T; Eschmann SM; Bultel YP; Hass P; Fleckenstein J; Thieme A; Stockinger M; Dieckmann K; Miederer M; Holl G; Rischke HC; Gkika E; Adebahr S; König J; Grosu AL;
Lancet Oncol; 2020 Apr; 21(4):581-592. PubMed ID: 32171429
[TBL] [Abstract][Full Text] [Related]
9. Performance of
Robin P; van Es N; Le Roux PY; Rondina M; Lecumberri R; Beckers M; Le Gal G; Salaun PY
Thromb Res; 2020 Oct; 194():153-157. PubMed ID: 32788108
[TBL] [Abstract][Full Text] [Related]
10.
Delluc A; Robin P
Thromb Res; 2022 May; 213 Suppl 1():S42-S45. PubMed ID: 36210560
[No Abstract] [Full Text] [Related]
11. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
[TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography combined with computed tomography as a screening tool for occult malignancy in patients with unprovoked venous thromboembolism: an observational study.
Chauchard M; Benali K; Papo T; Sacre K
Medicine (Baltimore); 2014 Nov; 93(21):e110. PubMed ID: 25380083
[TBL] [Abstract][Full Text] [Related]
13. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
14. Whole-Body
Lebech AM; Gaardsting A; Loft A; Graff J; Markova E; Bertelsen AK; Madsen JL; Andersen KF; Benzon EV; Helms M; Mathiesen LR; David KP; Kronborg G; Kjaer A
J Nucl Med; 2017 Jul; 58(7):1058-1064. PubMed ID: 28082437
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of occult malignancy in patients with unprovoked venous thromboembolism.
Robin P; Le Roux PY; Tromeur C; Planquette B; Prévot-Bitot N; Lavigne C; Pastre J; Merah A; Couturaud F; Le Gal G; Salaun PY
Thromb Res; 2017 Nov; 159():48-51. PubMed ID: 28978463
[TBL] [Abstract][Full Text] [Related]
16. Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.
Robertson L; Yeoh SE; Broderick C; Stansby G; Agarwal R
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD010837. PubMed ID: 30407621
[TBL] [Abstract][Full Text] [Related]
17. Effect of occult cancer screening on mortality in patients with unprovoked venous thromboembolism.
Robin P; Otten HM; Delluc A; van Es N; Carrier M; Salaün PY; Le Gal G
Thromb Res; 2018 Nov; 171():92-96. PubMed ID: 30268858
[TBL] [Abstract][Full Text] [Related]
18. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
[TBL] [Abstract][Full Text] [Related]
19. Extensive Computed Tomography versus Limited Screening for Detection of Occult Cancer in Unprovoked Venous Thromboembolism: A Multicenter, Controlled, Randomized Clinical Trial.
Prandoni P; Bernardi E; Valle FD; Visonà A; Tropeano PF; Bova C; Bucherini E; Islam MS; Piccioli A
Semin Thromb Hemost; 2016 Nov; 42(8):884-890. PubMed ID: 27764880
[TBL] [Abstract][Full Text] [Related]
20. Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study.
Lee JR; Kim JS; Roh JL; Lee JH; Baek JH; Cho KJ; Choi SH; Nam SY; Kim SY
Radiology; 2015 Mar; 274(3):764-71. PubMed ID: 25405771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
